Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Cancer Treat Rev. 2017 Jul 6;59:33–45. doi: 10.1016/j.ctrv.2017.06.006

Table 4.

Clinical trials of HDAC inhitors in sarcoma

HDAC Combination therapy Phase Number of sarcoma patients Dose
Panobinostat - II 47 20–40mg thrice weekly
Pracinostat - II 22 60 mg/day every other day for 3 of 4 weeks
Vorinostat - II 40 400 mg po qd for 28 day followed by a treatment-free period of 7 day
Abexinostat Doxorubicin I 22 Abexinostat: 45 mg/m2 twice daily administered on days 1 through 5
Doxorubicin: 75 mg/m2 on day 4 of a 3- week cycle
Belinostat Doxorubicin I/II 41 Belinostat:1000 mg/m2/day
Doxorubicin: 75mg/m2
Panobinostat Epirubicin I 21 Panobinostat: 50 mg
Epirubicin:75 mg/m2
Abexinostat Pazopanib I 6 Abexinostat: 30–45 mg/m2 twice Daily
Pazopanib:400–800 mg Daily